Moderna, an American biotechnology company, will open its first production plant in Africa in Kenya to make messenger RNA (mRNA) vaccines. The expenditure is estimated to be more than $500 million (Sh56.5 billion).
This approach will improve global vaccination and encourage long-term growth, as well as knowledge and technology transfer, as biotech companies face increasing pressure to share their expertise with manufacturers in global south countries.
